Robert W. Baird Thinks Editas Medicine’s Stock is Going to Recover

In a report released yesterday, Joel Beatty from Robert W. Baird maintained a Buy rating on Editas Medicine (EDITResearch Report), with a price target of $30.00. The company’s shares closed last Thursday at $19.15, close to its 52-week low of $9.59.

According to, Beatty is a 3-star analyst with an average return of 2.0% and a 47.8% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Editas Medicine with a $21.00 average price target, which is a 13.3% upside from current levels. In a report issued on August 3, Chardan Capital also reiterated a Buy rating on the stock with a $60.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $73.03 and a one-year low of $9.59. Currently, Editas Medicine has an average volume of 1.78M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Read More on EDIT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More